U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Thursday.

Following the market opening Thursday, the Dow traded down 0.05% to 48,972.29 while the NASDAQ declined 0.57% to 23,448.86. The S&P 500 also fell, dropping, 0.14% to 6,911.57.

Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Leading and Lagging SectorsIndustrials shares gained by 1.4% on Thursday.

In trading on Thursday, information technology stocks dipped by 1.4%.

Top Headline

Acuity Inc. (NYSE:AYI) reported fiscal first-quarter 2026 results Thursday, posting double-digit revenue growth and topping earnings expectations, driven by continued momentum in its intelligent building solutions business.

The company reported quarterly net sales growth of 20.2% year-over-year to $1.14 billion, in line with the analyst consensus estimate. It clocked an adjusted EPS of $4.69, beating the analyst consensus estimate of $4.59.

Equities Trading UP           

• Flyexclusive Inc (NYSE:FLYX) shares shot up 126% to $7.44 after the company was named an authorized Starlink Aviation dealer.
• Shares of Enliven Therapeutics Inc (NASDAQ:ELVN) got a boost, surging 59% to $24.55 after the company announced initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors.
• Nuvve Holding Corp (NASDAQ:NVVE) shares were also up, gaining 46% to $5.11 after the company announced it regained Nasdaq compliance.

Equities Trading DOWN

• Immuneering Corp (NASDAQ:IMRX) shares dropped 35% to $5.45. The company announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow up time.
• Shares of Acrivon Therapeutics Inc (NASDAQ:ACRV) were down 29% to $2.10 after the company announced ACR-368 Phase 2b endometrial cancer clinical data with EU expansion to accelerate enrollment, initial ACR-2316 clinical data, and ACR-6840, its next AP3-enabled development candidate, targeting CDK11.
• CorMedix Inc (NASDAQ:CRMD) was down, falling 25% to $8.33. The company announced preliminary fourth-quarter and FY25 revenue results.

CommoditiesIn commodity news, oil traded up 1.9% to $57.03 while gold traded down 0.6% at $4,436.20.

Silver traded down 4.7% to $73.925 on Thursday, while copper fell 2.5% to $5.7120.

Euro zone

European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.3%, while Spain's IBEX 35 Index rose 0.2%. London's FTSE 100 declined 0.1%, Germany's DAX fell 0.2% and France's CAC 40 fell 0.1% during the session.

Asia Pacific Markets

Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 1.63%, Hong Kong's Hang Seng Index declining 1.17%, China's Shanghai Composite slipping 0.07% and India's BSE Sensex falling 0.92%.

Economics

• U.S. initial jobless claims increased by 8,000 from the previous week to 208,000 in the week ending Jan. 3, compared to market expectations of 210,000.
• Nonfarm business sector labor productivity rose by 4.9% in the third quarter, following a revised 4.1% gain in the prior quarter.
• Unit labor costs in the nonfarm business sector fell by 1.9% in the third quarter, compared to market expectations of a 1.0% growth.
• The U.S. trade deficit shrank to $29.4 billion in October, recording the smallest gap since June 2009, versus a revised $48.1 billion gap in September and compared to market estimates of a $58.1 billion gap.

Now Read This:

• How To Earn $500 A Month From JPMorgan Stock Ahead Of Q4 Earnings

Photo via Shutterstock